The noninvasive markers that have significant correlation with staging of fibrosis (F stage) among NASH patients are platelet counts, AAR, FIB-4, WFA(+)-M2BP, IgA, and liver stiffness. Here, CD79A is linked to metabolic dysfunction-associated steatohepatitis.